Navigation Links
Study Demonstrates Percutaneous Tibial Nerve Stimulation Offers More Cost-Effective OAB Treatment Than Sacral Nerve Stimulation
Date:12/6/2012

MINNEAPOLIS, Dec. 6, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today highlighted results of a study that compared the cost effectiveness of neuromodulation therapies for Overactive Bladder (OAB) patients over two years of treatment.  The study compared percutaneous tibial nerve stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System versus sacral nerve stimulation (SNS). The article, "Costs of Neuromodulation Therapies for Overactive Bladder: Percutaneous Tibial Nerve Stimulation Versus Sacral Nerve Stimulation," will be published in the January 2013 edition of The Journal of Urology.  An abstract is now available online at http://dx.doi.org/10.1016/j.juro.2012.08.085.

The study used average Medicare national reimbursement amounts for the cost evaluation of these two neuromodulation therapies with clinically comparable outcomes. The initial cost of PTNS therapy was $1,773 for 12 weekly treatments compared to $1,857 for the SNS test stimulation.  Over two years, the cumulative discounted costs for PTNS therapy were estimated to be $3,850 compared to the SNS implant at $14,160.  Under a wide variety of conditions, PTNS remained significantly less costly than SNS over two years of therapy for those patients with OAB refractory to conservative and drug therapy.

Melissa Martinson, PhD, lead author of the study stated, "This study demonstrates significant cost savings to the healthcare system when PTNS is used instead of SNS.  In our current U.S. healthcare climate, maintaining the quality of care while also controlling costs is a central objective.  We believe that studies like this can con
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SANTA CLARA, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced the introduction of the cQUB™-1 (cQuest Ultrasound ... cQUB white-label ultrasound systems designed and manufactured by Cephasonics ... brand name and model number. Cephasonics will be showcasing ... 2014 being held this week in Chongqing, ...
(Date:10/22/2014)... , Oct. 22, 2014  Quest Diagnostics (NYSE: ... information services, today announced that its Board of Directors ... a director, effective December 1, 2014. Including Dr. Leiden, ... is the Chairman, President and CEO of Vertex Pharmaceuticals. ... scientific and commercial experience in the pharmaceutical and biotechnology ...
(Date:10/22/2014)... Calif. , Oct 22, 2014 Antigen ... Irvine, California , announced the receipt of ... Business Innovation Research award (SBIR) from the National Institute of Dental ... fund the development of a Pan-HIV Protein Microarray Chip, ... HIV-1 and HIV-2 subtypes and aid in the development ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
... 2011 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE AMEX: ... in China, today announced financial results for the quarter ended June ... Highlights Revenue increased 18% to $19.6 ... Cashflow from operations rose 10% to $3.6 million from $3.3 million ...
... N.J., Aug. 11, 2011 Pacira Pharmaceuticals, Inc. (Nasdaq: ... today announced financial results for the second quarter ended ... of its pre-commercial and launch strategies for EXPAREL™, and ... continued to aggressively execute our launch strategy for EXPAREL ...
Cached Medicine Technology:China Pharma Holdings, Inc. Reports Second Quarter 2011 Financial Results 2China Pharma Holdings, Inc. Reports Second Quarter 2011 Financial Results 3China Pharma Holdings, Inc. Reports Second Quarter 2011 Financial Results 4China Pharma Holdings, Inc. Reports Second Quarter 2011 Financial Results 5China Pharma Holdings, Inc. Reports Second Quarter 2011 Financial Results 6China Pharma Holdings, Inc. Reports Second Quarter 2011 Financial Results 7China Pharma Holdings, Inc. Reports Second Quarter 2011 Financial Results 8China Pharma Holdings, Inc. Reports Second Quarter 2011 Financial Results 9China Pharma Holdings, Inc. Reports Second Quarter 2011 Financial Results 10Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results 2Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results 3Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results 4Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results 5Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results 6Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results 7Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results 8Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results 9Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results 10
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded the ... in the field of establishing recovery community organizations. Bob ... when he retired, he set out to answer a couple ... , 1. Where are the people in recovery ... 2. Can the recovery community be organized to advocate for ...
(Date:10/25/2014)... The Wehrman Collaborative, LLC ... for disabled users by disabled users, has granted ... Mackin Educational Resources of Burnsville, Minnesota, for their ... to the Minnesota Alliance for Patient Safety of ... website. Both organizations have met WeCo’s ...
(Date:10/25/2014)... QueenBeeTickets.com has a variety of tickets for ... prices. Bob Seger & The Silver Bullet Band tickets ... are going on sale October 25 and are expected ... browse the selection of tickets for Bob Seger & ... singer is touring North America beginning next month, and ...
(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
(Date:10/25/2014)... Limbkeepers® announced today that they will be featured ... Jr, airing 1st QTR 2015 via Discovery Channel. Dates ... will focus on Limbkeepers® non compression knit sleeves, a ... arms, hands, and legs from abrasion, skin tears and ... help reduce injuries, allow for continued daily activities, and ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2
... It was a "common sense" decision to start the ... of the stroke belt. , "We wanted to give better ... of the Department of Neurology at the Medical College of ... 2000 and Hess and his colleagues were frustrated that nearly ...
... Researchers at UT Southwestern Medical Center have developed what ... new imaging technique to diagnose brain tumors. The unique test ... are located in areas of the brain too dangerous to ... a definitive diagnosis of cancer based on imaging of a ...
... , THURSDAY, Jan. 26 (HealthDay News) -- Popular cholesterol-lowering statins may ... a new study shows. Hepatitis B, an inflammation of the liver ... causes of liver cancer. This is not the first ... Other studies have hinted that these drugs may play a role ...
... (HealthDay News) -- Positive reinforcement, such as receiving small, ... seems to help patients with high blood pressure take ... of black Americans. The findings are significant because ... and death, the researchers from the Center for Healthful ...
... lung clearance index (LCI) is a sensitive non-invasive marker of ... according to a new study from Australian researchers. "We ... especially in the presence of airway inflammation and Pseudomonas aeruginosa," ... the Sydney Children,s Hospital. "LCI may not only be a ...
... Reporter , THURSDAY, Jan. 26 (HealthDay News) -- The rate ... dramatic upturn since 2004, reversing a trend of decline throughout ... place outside of the traditional hospital setting increased 29 percent ... to 0.72 percent -- almost 30,000 births -- according to ...
Cached Medicine News:Health News:Georgia Bio honors biotech company that enables stroke care 2Health News:Georgia Bio honors biotech company that enables stroke care 3Health News:Diagnostic brain tumor test could revolutionize care of patients 2Health News:Statins May Stave Off Liver Cancer in People With Hepatitis B 2Health News:Positive Reinforcement May Help Patients Take Their Meds 2Health News:Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index 2Health News:More U.S. Babies Born at Home: Report 2Health News:More U.S. Babies Born at Home: Report 3
... The Stryker Universal ACL Instrumentation ... utilized with a variety of anterior ... the Stryker Universal ACL Instrumentation system ... possible to obtain more reproducible anatomical ...
... Waived Drug Tests are easy to use; ... demonstrate excellent correlation with laboratory GC/MS testing ... in minutes instead of days. These tests ... in clinics, physician offices and rehabilitation centers., ...
... Test is an in vitro immunoassay ... of bladder tumor antigen in urine ... cancer. This test is indicated for ... management of bladder cancer patients ...
... Drug Screen Tests are available in 14 ... (Ecstasy). Designed using Microgenics Antibody Technology, the ... point of care immunoassay targeted to detect ... MDA and MDEA but no cross-reactivity to ...
Medicine Products: